Draftfcb buys New York pharma shop Hudson Global

Share this article:


Draftfcb Healthcare has bought Tarrytown, NY-based drug marketing shop Hudson Global.

The shop, founded in 2004, boasts a staff of 55 handling a roster of 20 clients in the pharma, diagnostic and biologics spaces. The agency will fall under the Draftfcb Healthcare umbrella but will continue to operate as a standalone unit under its old name and out of its Tarrytown office, led by its cofounders CEO/president Robert Blink and EVP Jason Goldklang. Blink will report to Draftfcb Healthcare and Draftfcb New York CEO Dana Maiman, and several employees will work regularly out of the network's Midtown Manhattan office (Tarrytown is around 25 miles north of Manhattan along the Hudson River).

Maiman praised the shop's expertise in medical education and sales training, along with its proprietary digital delivery technology, the SmartSeat platform, and exclusive video streaming partnership with MLB Advanced Media.

“It will enable tremendous video streaming and other proprietary technologies to be applied in the med ed and sales training areas,” said Maiman, adding that “We've been on the hunt for years and we wanted to acquire a company that had a very similar business approach and culture so that it would be seamless.”

Like Draftfcb Healthcare, said Maiman, “Their client roster spans blue chips to startups. They do such a broad array of programming – really diversified services, but they're better designed to answer specific business problems. They're extremely innovative and they'll drive revenue and sales for our clients' brands, and they're measure-able. That's why they're incredibly attractive and why they've been so successful.”

Interpublic Group's Draftfcb is among the giants of the healthcare marketing world, with not one but two conflict shops – NeON and Area 23 -- of its own.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...